



Huntington's disease research news.

In plain language. Written by scientists.

For the global HD community.

[News Glossary About](#)

[About](#)

[People FAQ Legal Funding Sharing Statistics Topics Contact](#)

[Follow](#)

[Follow](#)

[Podcast Twitter Facebook YouTube RSS Feed Email](#)

[Search HDBuzz](#)

Search HDBuzz



 [English](#)


[English](#) 

[čeština dansk Deutsch English español français italiano Nederlands norsk polski português svenska русский](#)

[中文 中文](#)

[More information...](#)



 **Are you looking for our logo?** You can download our logo and get information about how to use it on our [sharing page](#)

EuroBuzz News: Day 3

EuroBuzz news: Day 3. Ed and Jeff reporting from the European Huntington's Disease Network 2012 meeting in Stockholm



 By [Dr Jeff Carroll](#) September 16, 2012 Edited by [Dr Ed Wild](#)

Our third and final daily report from the European Huntington's Disease Network 2012 Meeting in Stockholm. Video of both EuroBuzz evening sessions will be available to watch on HDBuzz.net next week.

Sunday, September 16, 2012

10:47 - Welcome to day 3 of the European HD Meeting in Stockholm



Video of Ed and Jeff interviewing scientists in EuroBuzz will be available soon.

10:51 - **Ed:** Rachael Scahill (UCL, London) and Andrea Varrone (Stockholm) present an overview of brain imaging techniques help us understand HD. Brain scans have advanced dramatically over the next decade. They are still

telling us new and surprising things about HD

10:54 - **Ed:** Sarah Tabrizi (UCL, London) is head of the TRACK-HD study which has told us lots about early HD and helps design forthcoming trials. Despite detectable brain shrinkage before disease onset, people remain healthy - this means there is a lot to rescue

11:04 - **Jeff:** People have lots of problems with thinking and memory in HD - but this can be hard to measure in a clinic. Julie Stout (Monash, Melbourne) is looking for the best tests to use for HD patients to study “cognitive” function. Stout says that the way that tests used during trials are given to HD patients makes a big difference - this helps better plan future drug trials.

11:18 - **Jeff:** Anne-Catherine Bachoud-Levi (Henri-Mondor, Créteil) is also interested in understanding how thinking changes in HD. She’s studying different ways of questioning HD patients to understand how their cognitive abilities change over time. Picking which tests to use is really important - more sensitive tests allow us to run drug trials with less people, and a higher chance of success. Bachoud-Levi is working on new tasks, including things as simple as asking HD patients to do mental arithmetic.

11:26 - **Jeff:** Olivia Handley (UCL, London) is describing the REGISTRY database of HD patients in Europe - she’s the project manager. REGISTRY is a huge resource - there are 9,982 HD patients and control subjects, all of whom are volunteering information about themselves for study by scientists. The REGISTRY database let’s scientists ask questions about how HD develops - Handley reports that 25 studies have already been completed.

“ENROLL-HD will be open to every member of an HD family who wants to be engaged in research ”

11:31 - **Jeff:** The REGISTRY study is being merged with [COHORT-HD](#), another “[observational](#)” study of HD patients into a single large study called “ENROLL-HD”. ENROLL-HD will be open to every member of an HD family who wants to be engaged in research. There’ll be 60 sites in North America, 14 sites in Latin America, 146 sites in Europe, 2 sites in Asia and 7 sites in Australia/New Zealand. The ENROLL database will allow any qualified HD researcher to ask questions about HD, without revealing the identity of the participants.

11:55 - **Jeff:** Now taking the stage for the final talk of the EHDN meeting is Charle Sabine, HD family member and activist to provide his personal view of HD research.

12:42 - The meeting has now finished - great exchange of ideas and excitement. Look out for EuroBuzz videos soon.

The authors have no conflicts of interest to declare. [For more information about our disclosure policy see our FAQ...](#)



Learn more

[EHDN 2012 program at the EHDN web site](#) [REGISTRY](#) [ENROLL-HD](#) [Charles Sabine on Wikipedia](#) [HDBuzz on Twitter \(@HDBuzzFeed\)](#)

Topics

[observational mri ehdn](#)

[More...](#)

Related articles

[**Advances on many fronts in the battle against the protein that causes Huntington's disease**](#)

December 04, 2018

[HDBuzz Enrolls in Enroll-HD](#)

July 31, 2018

[A new way of thinking about trials to prevent Huntington's disease](#)

October 27, 2017

[Previous](#)[Next](#)

- Glossary
- **observational** A study in which measurements are made in human volunteers but no experimental drug or treatment is given
- **cohort** a group of participants in a clinical research study
- [Read more definitions in the glossary](#)

Huntington's disease research news.

In plain language. Written by scientists.

For the global HD community.

HDBuzz

[News](#)

[Previously featured](#)

[About](#)

[HDBuzz funding partners](#)

[Sites featuring HDBuzz content](#)

[New to research](#)

People


[Meet the team](#)

[Help us translate](#)

Follow HDBuzz

Sign up to our monthly email summary by entering your email address below or get more options on our [mailing list page](#)

<input type="text" value="Leave empty"/>	<input type="text" value="Email address"/>	<input type="button" value="Follow"/>
--	--	---------------------------------------



© HDBuzz 2011-2019. HDBuzz content is free to share, under a [Creative Commons License](#).

HDBuzz is not a source of medical advice. Please see our [Terms of use](#) for full details.

© HDBuzz 2011-2019. HDBuzz content is free to share, under a Creative Commons Attribution-ShareAlike 3.0 Unported License.

HDBuzz is not a source of medical advice. For more information visit hdbuzz.net

Generated on April 16, 2019 — Downloaded from <https://en.hdbuzz.net/096>